Unlock instant, AI-driven research and patent intelligence for your innovation.

CTLA-4 targeting antibody and preparation method and application thereof

A CTLA-4, antibody technology, applied in the field of biomedicine, can solve problems such as lack of activity and safety

Active Publication Date: 2019-09-24
JIANGSU HYAMAB PHARMA CO LTD
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] In order to overcome the current shortage of fully human CTLA-4 antibodies and the shortcomings of existing CTLA-4 antibodies in terms of activity and safety, the present invention provides a CTLA-4 antibody with high affinity and strong specificity and its preparation method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CTLA-4 targeting antibody and preparation method and application thereof
  • CTLA-4 targeting antibody and preparation method and application thereof
  • CTLA-4 targeting antibody and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0156] Antibody preparation

[0157] The sequence of the DNA molecule of the antibody or fragment thereof of the present invention can be obtained by conventional techniques, such as PCR amplification or genomic library screening. In addition, the coding sequences for the light and heavy chains can be fused together to form single-chain antibodies.

[0158] Once the relevant sequences are obtained, recombinant methods can be used to obtain the relevant sequences in large quantities. Usually, it is cloned into a vector, then transformed into a cell, and then the relevant sequence is isolated from the proliferated host cell by conventional methods.

[0159] In addition, related sequences can also be synthesized by artificial synthesis, especially when the fragment length is relatively short. Often, fragments with very long sequences are obtained by synthesizing multiple small fragments and then ligating them.

[0160] At present, the DNA sequence encoding the antibody of the ...

Embodiment 1

[0191] The preparation of embodiment 1CTLA-4 antibody

[0192] (1) Preparation of Immunogen A

[0193] The amino acid sequence Lys36-Asp161 of the extracellular region of the human CTLA-4 protein was cloned into the pCpC vector (purchased from Invitrogen, V044-50) with a human IgG Fc fragment (hFc), and the plasmid was prepared according to established standard molecular biology methods, For specific methods, see Sambrook, J., Fritsch, E.F., and Maniatis T. (1989). Molecular Cloning: A Laboratory Manual, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press). HEK293 cells (purchased from Invitrogen) were transiently transfected (PEI, Polysciences) and used FreeStyle TM 293 (Invitrogen) was expanded at 37°C. After 4 days, the cell culture fluid was collected, and the cell components were removed by centrifugation to obtain the culture supernatant containing the extracellular region of CTLA-4 protein. The culture supernatant was loaded onto a protein A aff...

Embodiment 2

[0213] Example 2 Identification of Chimeric Antibody

[0214] (1) Flow cytometry (FACS) detection of antibody binding to CTLA-4 expressing cells

[0215] Transfect the 293F cell line with the pIRES plasmid containing the full-length nucleotide sequence encoding human CTLA-4 described in step (2) of Example 1 to obtain a 293F stably transfected cell line containing human CTLA-4 (herein referred to as HEK293 -hCTLA-4 stable cell line), the pIRES plasmid with the full-length gene of monkey-derived CTLA-4, wherein the database accession number of the monkey-derived CTLA-4 nucleotide sequence is XM_005574014.1, was transfected into the HEK293 cell line HEK293 stably transfected cell line containing monkey CTLA-4 (referred to here as HEK293-cCTLA-4 stable cell line). The HEK293-hCTLA-4 stable cell line and the HEK293-cCTLA-4 stable cell line were expanded to 90% confluence in T-75 cell culture flasks, the medium was aspirated, and HBSS buffer (Hanks Balanced SaltSolution, purchased...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a CTLA-4 targeting antibody and a preparation method and application thereof. In particular, the invention discloses a novel fully human monoclonal antibody which targets CTLA-4. The invention also discloses a method for preparing the monoclonal antibody. The monoclonal antibody disclosed by the invention is capable of highly specifically binding to a CTLA-4 antigen, has high affinity and has remarkable antitumor activity and the like.

Description

technical field [0001] The present invention relates to the field of biomedicine, more specifically to a CTLA-4 antibody and its preparation method and application. Background technique [0002] The application of monoclonal antibodies is one of the most successful and transformative treatments in cancer treatment in the past 20 years. Compared with traditional chemical drugs, antibody drugs have higher specificity and lower toxicity. Although monoclonal antibody drugs have achieved continuous success, they still face many challenges [1] . [0003] The biggest drawback of murine monoclonal antibodies is the HAMA (human anti-mouse antibody) response it induces. Therefore, the mouse monoclonal antibody has great limitations in the diagnosis and treatment of tumors, organ transplantation and other diseases; the chimeric antibody still retains 30% of the mouse sequence, which can cause different degrees of HAMA reaction. Clinically, different chimeric antibodies have differe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61P35/00A61P31/12G01N33/68
CPCA61K2039/505A61P31/12A61P35/00C07K16/2818C07K2317/35C07K2317/56C07K2317/565C07K2317/76C07K2317/92G01N33/6872G01N2333/70521A61K39/395A61K39/44C07K2317/21C07K16/28G01N33/68C07K2317/24C07K2317/41C07K2317/74
Inventor 徐丽娜刘礼乐杨达志韦雨杏邵小慧张洁王美玲张瑜段清
Owner JIANGSU HYAMAB PHARMA CO LTD